Articles tagged with Immunogenicity
Researchers from Chiba University found that antibody therapeutics with stronger Fcγ receptor binding are more likely to be recognized as foreign and associated with higher anaphylaxis risk. High affinities for Fcγ receptors critical determinants of anaphylaxis, study suggests.
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
Researchers have identified tyrosine phosphatase 1B (PTP1B) as a key molecular target in immunogenic cell death (ICD), a type of regulated cell death that activates the immune system against cancer cells. Two platinum-containing compounds, Pt-NHC and PlatinER, trigger ICD by blocking PTP1B's enzymatic activity.
Researchers discovered five dominant patterns of protein-altering mutations that determine tumor visibility to the immune system. These 'fingerprints' help predict immunotherapy response and suggest a more personalized approach to cancer treatment.
The study found that mRNA-1083 induced higher immune responses than standard care influenza and COVID-19 vaccines, with an acceptable tolerability and safety profile. The vaccine met noninferiority criteria for all 4 influenza strains and SARS-CoV-2 across various age groups.
Researchers found basal cell carcinomas (BCCs) have an immune-excluded phenotype with minimal HLA-I expression, even in early development. A stem-like quiescent program suppressed APM genes, which could be reversed to enable BCC immunotherapy.
The article discusses the need for bioanalytical assays to measure immune responses to oligonucleotide therapeutic drugs, especially when they include carriers or conjugates. Highly specific antibodies may enhance the development and production of ONTs, expanding studies on their safety and efficacy.
The study utilized biocompatible polymethyl methacrylate microspheres for controlled antigen delivery, demonstrating improved immunogenicity of tetanus toxoid. Microsphere formulations showed significant immune response, with optimal polymer concentrations required to meet I.P. requirements.
Researchers developed biocompatible polymethyl methacrylate microspheres for controlled antigen delivery. The formulation resulted in efficient uptake by macrophages and other antigen-presenting cells, eliciting a notable immune response.
Researchers developed a lipid nanoparticle formulated miR-193a-3p mimic that enhances T cell mediated immune responses and induces immunogenic cell death in tumors. This study demonstrates the potential of this therapy to prolong animal survival and reduce metastasis, offering new hope for cancer treatment.
Researchers developed an innovative gene-writing technology based on R2 retrotransposons, enabling efficient and precise targeted gene integration in human cells. The en-R2Tg system achieves high gene integration specificity at the 28S rDNA safe harbor site, reducing mutagenesis risks.
The study reveals that hiPS-CMs induce a limited immune response but are rejected around 17-24 days after transplantation due to CD8+ T cells. Depletion of CD8+ T cells or treatment with tacrolimus prolongs sheet survival, highlighting the pivotal role of these immune cells.
Researchers describe a new concept for an immune response against cancer and aging using senescent cell-derived vaccines. The vaccines aim to stimulate the immune system against cancer cells and slow down or reverse aging-related diseases.
A recent study published in eClinical Medicine found that the GB510/AS03 vaccine elicited a stronger antibody immune response against the ancestral SARS-CoV-2 strain compared to ChAdOx1-S. The vaccine demonstrated robust safety and efficacy, with no significant safety concerns identified.
A team of researchers at Kyoto University has found that a deficiency in the enzyme B4GALT3 inhibits tumor growth in mice. The study shows that reduced glycosylation on T cell surfaces correlates with increased CD8+ immune cells infiltrating tumors.
A study of health care workers found that co-administering COVID-19 and influenza vaccines was not associated with reduced immune response or increased adverse events. The results support the co-administration of these vaccines, suggesting a safer and more efficient vaccination strategy.
The Phase 2a trial of OVX836 showed a notable signal of protection against influenza symptoms with an 84% level of protection compared to placebo. The vaccine candidate elicited significant humoral and cellular immune responses, highlighting its potential as a universal influenza vaccine.
A recent study published in the Journal of Clinical Immunology suggests that cutaquig infusions at higher infusion rates and volumes are well-tolerated and effective, with reduced infusion time, fewer injection sites, and improved compliance. The study results will be presented at the Clinical Immunology Society 2023 Annual Meeting.
The NVX-CoV2373 vaccine demonstrated strong safety and immunogenicity profiles in a clinical trial of over 2,200 adolescents. The study found the vaccine to be efficacious in preventing COVID-19, including the Delta variant.
A Phase 1 clinical trial of AAHI's thermostable, freeze-dried single-vial ID93 + GLA-SE vaccine candidate showed higher levels of antibodies and favorable cellular immune responses compared to the two-vial presentation. The results represent significant progress in global efforts to combat TB.
Researchers found that severe herpesvirus infections can strongly activate host cellular immunity, leading to a therapeutic effect on refractory adult T-cell leukemia/lymphoma. This activation may play an important role in the survival of patients with this intractable disease.
CHOP researchers have identified variants of a chaperone molecule that can enhance the loading of peptides across different HLA types, which could be used in cell therapy and immunization applications. The study found that chicken-derived TAPBPR proteins can react with multiple HLA allotypes and stabilize the empty MHC-I groove, boosti...
Researchers developed a CSIC vaccine that fully protects against SARS-CoV-2 infection in the brain and prevents associated brain damage. The MVA-CoV2-S vaccine candidate demonstrates sterilizing immunity and was effective even after reinfection with the virus.
A population-wide study in Chile shows that a mix-and-match approach to booster vaccination provides the best protection against COVID-19. The study found that heterologous booster vaccines, such as Pfizer-BioNTech or Astra Zeneca, were more effective than using the same vaccine for all three doses.
Scientists at Washington State University have discovered a novel theory that the innate immune system can respond differently to specific pathogens. This quality, known as immunological specificity, is driven by the nervous system and could provide a basis for finetuning an experimental treatment to fight infection.
A large group of patients with diverse cancer types received two doses of SARS-CoV-2 vaccines or one dose of the Johnson and Johnson vaccine, showing modestly impaired immune responses. Booster vaccine doses enhanced immunity in most patients.
A two-dose Ebola vaccine regimen has been found to be safe, well-tolerated, and produce a strong immune response in people over 1 year old. The study also supports the use of this regimen for Ebola virus disease prevention in children and adults.
A recent study found that up to a third of patients taking methotrexate had inadequate antibody levels after receiving the Pfizer-BioNTech COVID-19 vaccine. This is compared to healthy participants and those on other immunomodulatory drugs, who showed an adequate immune response.
The article reviews immunogenicity profiles of prominent SARS-CoV-2 vaccines in non-human primates and humans. Notably, Pfizer/BioNTech and Moderna vaccines have been authorized for use by the FDA following successful human clinical trials.
A new study shows a predictive link between VaxArray-measured potency and vaccine-induced immunogenicity in mice. The study found strong correlations between VaxArray assays and serum levels of antibodies targeting influenza hemagglutinin and neuraminidase.
The 2017 WRIB White Papers cover topics such as LCMS small molecules, hybrid LBA/LCMS biotherapeutics, and immunogenicity assays. An interactive Decennial Index of the White Papers provides a decade-long overview of recommendations on bioanalysis and biomarkers.
The study found that the HPV vaccine Cervarix provided 100% protection against HPV-16/18 infections over a period of 9.4 years, with high and sustained levels of IgG antibodies observed. The results suggest that the vaccine offered excellent persistence of protective immunity.